For the protection of our patients and staff, we continue to revise our guidelines to ensure that we are able to provide access to patients requiring oncology services. Effective immediately, we will allow one visitor to accompany patients to the practice exam rooms. For the infusion area will be considered case by case.
- • In view of the patient population (cancer risk stratification), we would continue to have mask use be an expectation everywhere at this point
- • Visitors will be provided with and asked to wear a mask
- • All visitors must provide confirmation of a negative COVID-19 test within three days (72 hours) of the visit or proof of complete vaccination (vaccination card, NYS Excelsior Pass Wallet app, etc.)
- • Visitors must undergo temperature checks upon entering the facility
- • Visitors must be advised to perform meticulous hand hygiene
- • Visitors must remain with the patient throughout the visit
- • All visitors must be greater than 18 years of age except in rare circumstance as determined by the cancer center leadership
Modified Guidelines on COVID Positive Patients, we will be treating our cancer patients as follows:
Asymptomatic COVID + patients
- Solid tumor:
– treatment to be held for 7 days following + test result
– patient may resume on day 8 to be treated - Malignant Heme (immunocompromised patients): Group A – see below
– treatment to be held for 14 days following + test result
– patient may resume on day 15 to be treated
Symptomatic COVID + patients
- Solid tumor:
– treatment to be held for 10 days from symptom onset
– may resume on day 11 from symptom onset, provided symptoms are improving, and afebrile for 48 hours without antipyretics - Malignant Heme (immunocompromised patients): Group A – see below
– treatment to be held for at least 14 days from symptom onset
– may resume as early as day 15, provided symptoms are improving, and afebrile for 48 hours without antipyretics
Group A:
• Receipt of CAR T (Chimeric Antigen Receptor) Cell Therapy (<or equal to 1 year)
• Receipt of solid-organ transplant and taking immunosuppressive therapy within 1 year or who received treatment for rejection within last 6 months
• HSCT (hematopoietic stem cell transplantation) (< or equal to 1 year)
• Presence of acute or chronic GVHD
• Acute Lymphocytic Leukemia-Undergoing Active Treatment
• Aplastic Anemia-Undergoing Active Treatment
• CLL- Undergoing Active Treatment
• AML-Undergoing Active Treatment
• Lymphoma on Active Treatment
• Hypogammaglobulinemia (e.g., Multiple Myeloma, CLL)
• Myeloma Disorder on Treatment
• Healthcare Workers with High Occupational Risk Exposure and Immunosuppressive condition or therapy
You may call us during office hours at (718)460-2300 if you have questions regarding these. You may also learn more about COVID 19 here.